Antigens, CD26/antagonists & inhibitors; Diabetes Mellitus, Type 2/drug therapy; Glucagon-Like Peptide 1/analogs & derivatives; Humans; Hypoglycemic Agents/pharmacology/therapeutic use
Abstract :
[en] Glucagon-like peptide-1 (GLP-1) is a gut hormone secreted in response to a meal ingestion, which is rapidly degraded by a specific enzyme, dipeptidylpeptidase-4 (DPP-4). It enhances insulin secretion in a glucose-dependent manner, inhibits glucagon secretion, retards gastric emptying,... Two pharmacological approaches have been developed to increase the abnormally low GLP-1 levels in type 2 diabetic patients: either to subcutaneously inject an agent closed to GLP-1 (exenatide), which is partially resistant to the action of DPP-4, either to orally administer a selective DPP-4 inhibitor (sitagliptin,...). These new drugs offer improved blood glucose control of type 2 diabetic patients, without inducing hypoglycaemia and with favourable effects on body weight.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Radermecker, Régis ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Philips, Jean-Christophe ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Paquot, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
French
Title :
Les incretinomimetiques et incretinopotentiateurs dans le traitement du diabete de type 2.
Alternative titles :
[en] Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes
Scheen AJ. Pathophysiology of insulin secretion. Ann Endocrinol (Paris) 2004;65:29-36.
* Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet 2005;365:1333-46.
* Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72 and Diabetologia 2006;49:1711-21.
Rendell M. The role of sulphonyl ureas in the management of type 2 diabetes mellitus. Drugs 2004;64:1339-58.
Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001;358:1709-16.
Krentz AJ, Bailey CJ. Oral antidiabetic agents. Current role in type 2 diabetes mellitus. Drugs 2005;65:385-411.
Gautier JF, Fetita S, Sobngwi E, Salaun-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 2005;31:233-42.
** Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705.
Scheen AJ. Le glucagon-like peptide-1 (GLP-1), nouvelle cible dans le traitement du diabete de type 2. Rev Med Liège 2007;62:216-9.
Keating GM. Exenatide. Drugs 2005;65:1681-92.
DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.
Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 2005;143:559-69.
Vilsbell T. Liraglutide :A once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus. Expert Opin Invest Drugs 2007;16:231-7.
* Idris S, Donnelly R. Dipeptidyl peptidase-IV inhibitors: A major new class of oral antidiabetic drug. Diab Obes Metab 2007;9:153-65.
Lyseng-Williamson KA. Sitagliptin. Drugs 2007;67:587-97.
Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.
Nauck M, Meiniger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone:A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205.
